Wockhardt Limited has announced the incorporation of three new wholly-owned step-down subsidiaries through its existing subsidiary, Wockhardt Bio AG. The new entities are Wockhardt Swiss AG, incorporated in Zug, Switzerland, and Wockhardt Suisse USA Holding Corporation and Wockhardt Suisse USA LLC, both incorporated in Delaware, USA. Wockhardt Swiss AG was incorporated on December 1, 2025, with a capital of CHF 100,000.00. Its primary object is to channelize the company's antibiotic products. Wockhardt Suisse USA Holding Corporation and Wockhardt Suisse USA LLC were both incorporated on December 11, 2025, each with a capital of USD 50,000.00. These US-based entities will facilitate the distribution of Wockhardt's antibiotic and other products across the United States. All three newly incorporated subsidiaries are in the pharmaceuticals industry and have not yet commenced business operations. The incorporation is considered a cash consideration transaction. The company stated that the delay in intimation was due to an inadvertent administrative oversight and is being made upon realization of the omission.
